Immutep's Lead Cancer Drug Shows Promising 2-Year Survival Data In Lung Cancer Trial

Core Insights - Immutep Limited released promising data from the INSIGHT-003 Phase 1 trial of eftilagimod alpha in combination with Keytruda and chemotherapy for first-line treatment of metastatic non-squamous non-small cell lung cancer patients [1][2] Group 1: Survival Data - The trial showed a median Overall Survival (OS) of 32.9 months and a median Progression-Free Survival (PFS) of 12.7 months with a 24-month OS rate of 81.0% [1] - This data significantly outperforms historical controls, which reported a median OS of 22.0 months and a median PFS of 9.0 months [2] Group 2: Overall Response Rate (ORR) - The trial demonstrated a significant improvement in Overall Response Rate (ORR) across all levels of PD-L1 expression, with an ORR of 75.0% for high PD-L1, 58.8% for low PD-L1, and 47.4% for negative PD-L1 [3] - In the overall patient population, the trial achieved a 55.0% ORR and an 87.5% Disease Control Rate (DCR) [3] Group 3: Patient Demographics and Future Updates - The trial is biased towards low and negative PD-L1 patients, who typically show less response to anti-PD-1 therapy, with a 52.8% ORR and 86.1% DCR in this subgroup [3] - INSIGHT-003 is nearing completion of patient enrollment, with additional data updates expected in 2025 and beyond [4] Group 4: Market Reaction - Following the announcement, Immutep's stock rose by 9.6%, reaching $2.05 [4]